Kura Oncology Stock Forecast, Price & News

-0.88 (-2.99 %)
(As of 04/16/2021 04:00 PM ET)
Today's Range
Now: $28.59
50-Day Range
MA: $28.53
52-Week Range
Now: $28.59
Volume391,723 shs
Average Volume740,641 shs
Market Capitalization$1.89 billion
P/E RatioN/A
Dividend YieldN/A
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Kura Oncology logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KURA
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$4.83 per share


Net Income$-63,140,000.00


Market Cap$1.89 billion
Next Earnings Date5/3/2021 (Estimated)


Kura Oncology (NASDAQ:KURA) Shares Down 5%
April 13, 2021 |
KURA Crosses Above Key Moving Average Level
April 1, 2021 |
Kura Oncology (NASDAQ:KURA) Shares Gap Up to $26.61
April 1, 2021 |
Is KURA Stock A Buy or Sell?
March 29, 2021 |
Kura Oncology (NASDAQ:KURA) Stock Price Up 5.6%
March 25, 2021 |
RSI Alert: Kura Oncology (KURA) Now Oversold
February 25, 2021 |
First Week of KURA March 19th Options Trading
January 20, 2021 |
KURA Jul 2021 20.000 put
January 4, 2021 |
KURA Jul 2021 40.000 put
January 4, 2021 |
Is KURA A Good Stock To Buy According To Hedge Funds?
December 22, 2020 |
See More Headlines


Overall MarketRank

1.56 out of 5 stars

Medical Sector

432nd out of 2,025 stocks

Pharmaceutical Preparations Industry

211th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
-0.88 (-2.99 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

Is Kura Oncology a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Kura Oncology stock.
View analyst ratings for Kura Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than Kura Oncology?

Wall Street analysts have given Kura Oncology a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kura Oncology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for Kura Oncology

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) released its quarterly earnings data on Wednesday, February, 24th. The company reported ($0.45) EPS for the quarter, meeting the consensus estimate of ($0.45).
View Kura Oncology's earnings history

How has Kura Oncology's stock price been impacted by COVID-19 (Coronavirus)?

Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KURA shares have increased by 196.3% and is now trading at $28.59.
View which stocks have been most impacted by COVID-19

What price target have analysts set for KURA?

11 brokers have issued 12-month price objectives for Kura Oncology's shares. Their forecasts range from $24.00 to $56.00. On average, they expect Kura Oncology's share price to reach $39.55 in the next twelve months. This suggests a possible upside of 38.3% from the stock's current price.
View analysts' price targets for Kura Oncology
or view top-rated stocks among Wall Street analysts.

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the following people:
  • Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 52, Pay $908.26k)
  • Dr. Marc Grasso, CFO & Chief Bus. Officer (Age 48, Pay $630.86k)
  • Ms. Kathleen Ford, Chief Operating Officer (Age 74, Pay $492.28k)
  • Mr. James E. Basta J.D., Esq., Chief Legal Officer, Chief Compliance Officer & Corp. Sec. (Age 55, Pay $168.94k)
  • Mr. Pete De Spain, VP of Investor Relations & Corp. Communications
  • Dr. Blake Tomkinson M.B.A., Ph.D., Head of Portfolio Strategy & Program Management
  • Ms. Kirsten Flowers, Chief Commercial Officer (Age 46)
  • Dr. Roger Bakale Ph.D., VP and Head of CMC, Clinical & Commercial Manufacturing
  • Dr. Stephen Dale M.D., Chief Medical Officer
  • Dr. Nic G. Scalfarotto, Sr. VP of Regulatory Affairs

Who are some of Kura Oncology's key competitors?

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Pacer Advisors Inc. (0.00%). Company insiders that own Kura Oncology stock include Antonio Gualberto, Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends for Kura Oncology

Which major investors are selling Kura Oncology stock?

KURA stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have sold Kura Oncology company stock in the last year include Kathleen Ford, Marc Grasso, and Troy Edward Wilson.
View insider buying and selling activity for Kura Oncology
or view top insider-selling stocks.

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $28.59.

How much money does Kura Oncology make?

Kura Oncology has a market capitalization of $1.89 billion. The company earns $-63,140,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.

How many employees does Kura Oncology have?

Kura Oncology employs 88 workers across the globe.

What is Kura Oncology's official website?

The official website for Kura Oncology is

Where are Kura Oncology's headquarters?

Kura Oncology is headquartered at 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company can be reached via phone at 858-500-8800 or via email at [email protected]

This page was last updated on 4/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.